Celltrion Inc (068270) - Total Liabilities
Based on the latest financial reports, Celltrion Inc (068270) has total liabilities worth ₩4.98 Trillion KRW (≈ $3.38 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Celltrion Inc growing its equity to track the company's year-over-year net asset growth rate.
Celltrion Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Celltrion Inc's total liabilities have evolved over time, based on quarterly financial data.
Celltrion Inc Competitors by Total Liabilities
The table below lists competitors of Celltrion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fortis Inc
TO:FTS
|
Canada | CA$50.23 Billion |
|
GE HealthCare Technologies Inc.
NASDAQ:GEHC
|
USA | $26.23 Billion |
|
ResMed Inc
NYSE:RMD
|
USA | $2.29 Billion |
|
Hannover Rück SE
F:HNR1
|
Germany | €57.40 Billion |
|
Dover Corporation
NYSE:DOV
|
USA | $6.02 Billion |
|
Raymond James Financial Inc.
NYSE:RJF
|
USA | $76.19 Billion |
|
China State Construction Engineering Corp Ltd
SHG:601668
|
China | CN¥2.60 Trillion |
|
Svenska Handelsbanken AB (publ)
ST:SHB-A
|
Sweden | Skr3.55 Trillion |
Liability Composition Analysis (2007–2025)
This chart breaks down Celltrion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Celltrion Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celltrion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celltrion Inc (2007–2025)
The table below shows the annual total liabilities of Celltrion Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩4.98 Trillion ≈ $3.38 Billion |
+43.37% |
| 2024-12-31 | ₩3.48 Trillion ≈ $2.36 Billion |
+24.48% |
| 2023-12-31 | ₩2.79 Trillion ≈ $1.89 Billion |
+72.60% |
| 2022-12-31 | ₩1.62 Trillion ≈ $1.10 Billion |
-0.39% |
| 2021-12-31 | ₩1.62 Trillion ≈ $1.10 Billion |
+1.96% |
| 2020-12-31 | ₩1.59 Trillion ≈ $1.08 Billion |
+61.40% |
| 2019-12-31 | ₩986.73 Billion ≈ $668.70 Million |
+8.69% |
| 2018-12-31 | ₩907.85 Billion ≈ $615.24 Million |
+2.74% |
| 2017-12-31 | ₩883.60 Billion ≈ $598.80 Million |
+7.37% |
| 2016-12-31 | ₩822.97 Billion ≈ $557.72 Million |
-12.30% |
| 2015-12-31 | ₩938.39 Billion ≈ $635.93 Million |
-3.72% |
| 2014-12-31 | ₩974.60 Billion ≈ $660.48 Million |
+9.34% |
| 2013-12-31 | ₩891.38 Billion ≈ $604.07 Million |
+30.55% |
| 2012-12-31 | ₩682.77 Billion ≈ $462.70 Million |
+34.46% |
| 2011-12-31 | ₩507.77 Billion ≈ $344.11 Million |
+35.20% |
| 2010-12-31 | ₩375.57 Billion ≈ $254.52 Million |
+37.31% |
| 2009-12-31 | ₩273.53 Billion ≈ $185.37 Million |
-2.15% |
| 2008-12-31 | ₩279.55 Billion ≈ $189.45 Million |
+701.67% |
| 2007-12-31 | ₩34.87 Billion ≈ $23.63 Million |
-- |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more